Drive patient identification and market development for SMA by building and executing against a territory strategy, account and customer specific plans thereby achieving and exceeding sales goals.
Continuously assesses sales opportunities within markets and accounts to maintain and grow their business.
Educate and connect HCPs to Scholar Rock services.
Scholar Rock is a late-stage global biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. They are a global leader in myostatin biology, with a commitment to unlocking fundamentally different treatment approaches, powered by the application of a proprietary platform.
Drive achievement of ambitious sales targets by developing and executing strategic account and territory plans.
Build and sustain trusted, senior-level relationships with key decision-makers and influencers at customer organizations.
Lead complex sales cycles end-to-end, from opportunity discovery and solution development through negotiation, contracting, and close.
Clarivate is a global leader in providing trusted and transformative intelligence across the spectrum of knowledge, research, and innovation. The company brings together enriched data, insights, analytics, and workflow solutions to fuel the world's greatest breakthroughs and has a global, collaborative team focused on delivering customer value.
Achieve planned sales and patient access objectives for the assigned geography.
Engage with Healthcare Professionals to educate them on product clinical information and access resources.
Collaborate with cross-functional partners and manage accounts to resolve reimbursement issues and ensure compliance.
Braeburn delivers solutions for people living with the serious consequences of opioid use disorder. The company fosters a culture of authenticity and empowerment, encouraging innovation and amplifying all voices to help patients begin and sustain recovery.